Cerebrospinal Fluid Testing for Childhood Brain Tumors: What Patients and Families Need to Know

Table of Contents

• Key Points
• Background: Why This Research Matters
• How CSF Is Already Used in Childhood Brain Tumors
• Current CSF Applications by Tumor Type (Detailed Table)
• Why CSF Is Often Better Than Blood for Brain Tumors
• What Determines Whether Tumor Signals Appear in CSF
• Detailed Signal Factors by Tumor Context
• From Tumor to Clinical Answer: A Biological Framework
• Pre-Analytical and Technical Factors That Determine Test Success
• Clinical Implications for Patients and Families
• Limitations and Cautions
• Practical Recommendations
• Frequently Asked Questions
• Source Information

Key Points

• CSF testing is already used in pediatric neuro-oncology for staging tumor spread and, in germ cell tumors, for markers such as AFP and beta-hCG.
• CSF is often more informative than blood for brain tumors because it is physically closer to the tumor and less limited by the blood–brain barrier.
• CSF liquid biopsy complements, but does not replace, tissue biopsy, imaging, plasma testing, or conventional cytology.
• A negative CSF result does not rule out disease; false negatives are common, especially in low-grade or well-circumscribed tumors.
• CSF testing is most useful when results could change staging, radiation dose, treatment intensity, monitoring, or trial eligibility.

Background: Why This Research Matters

Pediatric brain and other central nervous system (CNS) tumors — tumors that arise in the brain and spinal cord — remain a leading cause of cancer-related illness and death in children and adolescents. Population-based data consistently show that they are the most common solid tumors of childhood and the leading cause of cancer death in this age group. This makes the need for diagnostic strategies that are both biologically informative and clinically practical especially urgent.

At the same time, pediatric neuro-oncology has undergone a fundamental shift away from diagnosing tumors by looking at their shape and appearance under a microscope (morphology-centered diagnosis). Instead, the field is moving toward an integrated molecular classification, in which genomic features (changes in DNA) and epigenomic features (chemical tags on DNA that control gene activity) increasingly shape how tumors are defined, how risk is stratified, and how treatment decisions are made.

Yet translating these advances into clinical practice still depends mostly on tumor tissue obtained during surgery or biopsy. Although tissue remains the diagnostic gold standard, tissue-based assessment has important limits in children. Neurosurgical sampling may be difficult, hazardous, or intentionally delayed when tumors sit deep in the brain, in the midline, or in areas that control critical functions (so-called "eloquent" tumors). Small specimens may be inadequate for comprehensive molecular profiling. And even when tissue is available, it represents only a single snapshot in space and time of a disease that is biologically evolving.

These constraints matter enormously in pediatric CNS tumors, where repeat sampling is often impractical and where timely molecular information can directly change diagnosis and treatment selection.

Against this background, cerebrospinal fluid (CSF) — the clear, colorless fluid that bathes the brain and spinal cord — has become a particularly informative "liquid biopsy" compartment for primary CNS tumors. Because CSF is anatomically adjacent to the brain and spinal cord and lies close to intracranial disease, it is generally more informative than plasma (the liquid portion of blood) for detecting tumor-derived material in CNS cancers. This enrichment reflects two things: the physical proximity of the fluid to the tumor, and the limited transfer of tumor-derived nucleic acids (DNA and RNA) across the blood–brain barrier into the general bloodstream.

As a result, CSF can provide access not only to cell-free DNA (cfDNA — DNA fragments floating freely in fluid, outside of cells) and circulating tumor DNA (ctDNA — the portion of that free DNA that comes specifically from the tumor), but also to circulating tumor cells (CTCs — whole tumor cells shed into fluid), various RNA species, extracellular vesicles (EVs — tiny membrane-bound packages released by cells), proteins, and metabolites. Together these form a multi-dimensional molecular window into pediatric brain tumors.

Historically, CSF was used mainly for staging, most notably to look for tumor cells under the microscope (cytology) to assess leptomeningeal dissemination — spread of tumor through the thin, fluid-lined membranes that cover the brain and spinal cord. That role remains clinically important, but it no longer captures the full diagnostic potential of the fluid. Recent studies show that CSF-derived analytes (substances measured in the fluid) can support mutation detection, copy-number profiling (counting how many copies of genes are present), methylation-based classification, and longitudinal disease monitoring across multiple pediatric CNS tumor types. In embryonic tumors (tumors arising from immature, developing cells), a technique called low-pass whole-genome sequencing (LP-WGS) applied to CSF-derived cfDNA has shown greater sensitivity than conventional cytology for detecting tumor at the time of staging, while also enabling serial assessment of how the tumor's genome evolves over time.

Even more recently, methylation-based studies have pushed CSF analysis beyond mutation detection toward molecular classification itself, including in samples with very low amounts of input DNA and in real-world pediatric settings. Taken together, these studies show that CSF has uses far beyond cytological staging — it is a biologically privileged liquid-biopsy compartment with expanding relevance for diagnosis, classification, and disease monitoring in pediatric neuro-oncology.

What This Review Adds

The authors make a specific conceptual contribution: they frame CSF liquid biopsy not as a broadly applicable replacement for tissue, imaging, plasma, or conventional cytology, but as a decision-dependent translational tool. In other words, CSF testing is most useful at specific clinical decision points where it provides information that cannot be reliably obtained from less invasive or already-established methods — and where that information is likely to change diagnosis, risk stratification, treatment selection, monitoring, relapse detection, or eligibility for a clinical trial.

How the Authors Gathered Evidence

This article is a narrative review, meaning it synthesizes current evidence and translational concepts rather than providing a systematic review or meta-analysis. The authors identified relevant literature through searches of PubMed/MEDLINE, Web of Science, Scopus, and Google Scholar, supplemented by manually screening reference lists from selected primary studies, review articles, and clinical reports. The search was last updated on 26 May 2026.

Search terms combined phrases such as "cerebrospinal fluid," "CSF," "liquid biopsy," "circulating tumor cell," "CTC," "cell-free DNA," "cfDNA," "circulating tumor DNA," "ctDNA," "DNA methylation," "methylation profiling," "RNA," "microRNA," "extracellular vesicles," "proteomics," "metabolomics," "pediatric brain tumor," "medulloblastoma," "diffuse midline glioma," "DIPG," "ependymoma," "atypical teratoid/rhabdoid tumor," "AT/RT," "pediatric low-grade glioma," and "intracranial germ cell tumor." Additional terms included "measurable residual disease," "minimal residual disease," "molecular monitoring," "leptomeningeal dissemination," "pre-analytical variables," "blood contamination," "CSF sampling," and "clinical implementation."

The authors prioritized original studies, clinically relevant cohort studies, translational reports, technical validation studies, and high-quality reviews. Adult studies and studies of leptomeningeal disease were included selectively when pediatric data were limited and the findings were mechanistically or technically relevant. Non-peer-reviewed material, purely speculative reports, and studies without clear relevance were generally excluded. Because this was not a systematic review, no formal risk-of-bias assessment or quantitative evidence grading was performed.

How CSF Is Already Used in Childhood Brain Tumors

CSF is already an established clinical specimen in pediatric neuro-oncology — even before modern liquid-biopsy technologies are considered. Its most established role is in assessing dissemination (spread). A postoperative lumbar CSF sample (obtained by a lumbar puncture, often called a spinal tap) is interpreted alongside neuraxis MRI (imaging of the entire brain and spinal cord) to evaluate leptomeningeal spread in tumors known to have seeding potential. This applies particularly to medulloblastoma (MB), ependymoma, atypical teratoid/rhabdoid tumor (AT/RT), and selected intracranial germ cell tumors (iGCTs).

In medulloblastoma, a positive CSF cytology (tumor cells seen in the fluid) remains clinically important because it corresponds to "M1 disease" — one of the M-staging categories used to describe how far a tumor has spread. M1 disease can alter risk assignment and adjuvant treatment intensity, including whether craniospinal irradiation (radiation to the whole brain and spine) is used and at what dose. In ependymoma and AT/RT, the role of CSF is more selective and depends on the specific tumor type, but positive findings may still influence dissemination staging and treatment intensification.

CSF is also used for established disease-specific biochemical markers, showing that its clinical role extends beyond looking at cells under a microscope. This is most evident in intracranial germ cell tumors, where CSF levels of alpha-fetoprotein (AFP — a protein produced by certain tumors) and beta-human chorionic gonadotropin (β-hCG — a hormone produced by certain tumors) are integrated into diagnosis, disease classification, risk stratification, and response assessment during treatment. In this setting, CSF functions as a clinically actionable biochemical specimen that helps distinguish germinoma (a specific type of germ cell tumor) from non-germinomatous germ cell tumor (NGGCT) and supports response assessment during therapy.

This precedent is important because it shows that molecular CSF applications extend an existing clinical role rather than creating a completely new one from scratch.

However, the informational range of current CSF practice remains limited relative to the needs of modern pediatric neuro-oncology. Conventional CSF assessment is strongest for dissemination staging and selected biochemical applications, but much weaker for molecular classification, treatment-response assessment, minimal residual disease detection (detecting tiny amounts of leftover disease), and tracking resistance. Its performance is also shaped by the sampling compartment and the perioperative context — because lumbar, ventricular, and shunt-derived specimens are not diagnostically equivalent. Early postoperative samples are particularly vulnerable to blood contamination or procedure-related confounding.

These limitations do not diminish the clinical importance of current CSF practice. Instead, they explain why molecular augmentation of CSF has become increasingly important.

Current CSF Applications by Tumor Type (Detailed Table)

The table below summarizes how CSF testing is used today across major pediatric CNS tumor types, along with the main limitations of each use.

• Medulloblastoma (all molecular subgroups): CSF cytology, protein, and glucose are measured. Lumbar puncture for cytology is performed postoperatively (at least 14 days after surgery) and combined with neuraxis MRI for Chang staging. Positive cytology (M1) upstages the tumor to high-risk disease and drives craniospinal irradiation dose and adjuvant chemotherapy intensity. Key limitations: Cytology sensitivity is only about 30–70%, and false negatives are common. Pre-operative lumbar puncture is contraindicated because of herniation risk (dangerous brain swelling). Post-surgical blood contamination confounds interpretation. Molecular subgroup status is not captured by CSF testing.
• Ependymoma (intracranial and spinal): Lumbar puncture for leptomeningeal staging at diagnosis and relapse; routine use varies by center and by spine MRI findings. Positive CSF cytology can shift management toward craniospinal irradiation. Key limitations: Very low clinical yield at diagnosis; cytology is rarely positive when the spine MRI is negative. Overall rates of leptomeningeal-positive (M+) disease are low, about 5–10% at diagnosis. Molecular subtypes (such as ZFTA-fusion ependymoma) are not detectable by conventional CSF testing.
• CNS germ cell tumors (germinoma and non-germinomatous): AFP, β-hCG, and PLAP (placental alkaline phosphatase) measured in CSF, plus cytology. Measurement is essential for diagnosis, disease classification, baseline risk assessment, and response assessment during treatment. Elevated CSF AFP or β-hCG supports diagnosis of non-germinomatous GCT, informs classification and treatment intensity, and a CSF-to-serum ratio may help localize the tumor. Marker decline or normalization during therapy supports response assessment. Key limitations: Normal markers do not exclude GCT, particularly pure germinoma. AFP elevation may be physiologic (normal) in infants under 1 year of age. CSF PLAP lacks standardization across laboratories. CSF tumor markers are not routinely used for surveillance after therapy in all patients and should be interpreted according to protocol, tumor subtype, and clinical context.
• Diffuse midline glioma, H3K27M-altered (including DIPG): No single conventional analyte. Lumbar puncture is not routinely performed; diagnosis is based on MRI with or without biopsy. CSF cytology has no established staging role; lumbar puncture may be contraindicated for brainstem location. Key limitations: No validated role in current standard of care; leptomeningeal dissemination occurs but is not routinely staged by CSF. Emerging ctDNA/cfDNA approaches remain investigational.
• AT/RT (SMARCB1/SMARCA4-deficient): CSF cytology for leptomeningeal dissemination, which is present in about 30% of patients at diagnosis and drives upfront craniospinal therapy decisions, including high-dose chemotherapy-based approaches. Key limitations: M-stage is a key prognostic variable, and M+ disease is associated with inferior survival. Cytology has a high false-negative rate despite radiologic dissemination. Very young age (most patients are under 3 years) complicates lumbar puncture safety and CSF interpretation. Rapid disease progression limits the usefulness of sequential sampling.
• Pediatric high-grade glioma / glioblastoma (non-DMG, e.g., HGG, GBM): Lumbar puncture is not routinely used for staging; performed if leptomeningeal spread is suspected clinically or radiologically at relapse. Key limitations: No validated CSF-based staging system exists. CSF cytology has limited sensitivity for sparse leptomeningeal tumor cells and may be negative despite radiologic leptomeningeal spread. Lumbar puncture may be unsafe in patients with mass effect, edema, or raised intracranial pressure. No tumor-specific CSF biomarker is currently used in routine care for pediatric non-DMG HGG/GBM.

In short, CSF already has an established role in formal disease assessment across several pediatric CNS tumor types — but that role is narrow and does not yet meet the full molecular needs of modern neuro-oncology.

Why CSF Is Often Better Than Blood for Brain Tumors

The anatomical relationship between CSF and brain tumors provides the biological basis for CSF liquid biopsy in pediatric CNS tumors and explains why CSF is often the preferred liquid-biopsy matrix for primary CNS malignancies. Rather than simply restating the general "CSF versus plasma" rationale, the authors focus on the biological factors that determine whether a given CSF sample is likely to contain informative tumor-derived signals.

But the biological informativeness of CSF is not uniform across tumors. Signal intensity is shaped by how much the tumor touches the ventricular, subarachnoid, or leptomeningeal spaces. Deeply embedded (parenchymal) or well-circumscribed (compact, well-contained) lesions are far less likely to release detectable tumor-derived material into the fluid. Disseminated disease further amplifies the signal by increasing the tumor surface exposed to CSF pathways — particularly in embryonic tumors with spread along the spinal axis, and in other tumors that seed the leptomeninges.

Tumor biology also shapes yield: high-grade, invasive, and necrotic tumors (tumors with dead tissue inside them) typically release more cfDNA and protein than slow-growing, low-grade lesions. By contrast, post-treatment, low-burden disease states may generate only sparse or intermittent signal despite persistent disease.

Consequently, CSF liquid biopsy should be interpreted in relation to tumor anatomy, dissemination pattern, treatment context, sampling route, assay platform, and the specific clinical question being asked.

Interpreting Positive and Negative CSF Findings

These determinants also frame how positive and negative CSF findings should be read. A positive result may indicate close tumor proximity to CSF spaces, overt dissemination, high cellular turnover, residual disease, or emerging relapse biology. Conversely, a negative result does not exclude disease. It may reflect low shedding, limited CSF contact, a low tumor fraction in the sample, or treatment-related suppression of analyte release.

In other words, CSF provides a biologically meaningful but selective view of tumor burden — not a universal surrogate across all pediatric CNS tumors. CSF is therefore best viewed as a compartment-specific readout whose clinical value depends not only on how well the test performs in the lab, but also on how, when, and from where the sample is obtained.

What Determines Whether Tumor Signals Appear in CSF

The authors describe five main factors that influence the likelihood of detecting informative tumor signal in CSF. Together, they help clinicians predict when a CSF test is likely to be useful and when it may be falsely reassuring.

• High signal (↑): Tumor–CSF interface contact. Direct shedding of tumor cells, DNA, proteins, and extracellular vesicles into CSF is facilitated by physical proximity to the ependymal surface (the lining of the brain's fluid-filled spaces) or the subarachnoid space. Detection rates of ctDNA and tumor-derived protein are significantly higher when the tumor abuts a CSF-contiguous surface. Examples include intraventricular ependymoma, choroid plexus tumors, tectal and pineal region tumors, and third-ventricular craniopharyngioma.
• Very high signal (↑↑): Leptomeningeal dissemination. Dissemination provides a large, diffuse tumor–CSF interface, broadly amplifying shedding of all analyzed substance classes — cells, ctDNA, protein, and extracellular vesicles. Sensitivity for liquid biopsy analytes peaks in the context of macroscopic spread, and even conventional cytology sensitivity rises with higher M-stage. Examples include metastatic medulloblastoma (M2–M3 spread), AT/RT with spinal drop metastases, disseminated CNS germ cell tumors, and leptomeningeal relapse of high-grade glioma.
• High signal (↑): High-grade biology. Tumors with high mitotic activity (rapid cell division), disrupted blood vessel growth, and invasive growth patterns release more cfDNA and protein per unit of tumor mass. High-grade histology correlates with a greater fraction of CSF ctDNA independent of tumor location. Elevated CSF protein is seen more often in high-grade versus low-grade pediatric CNS tumors. Examples include pediatric glioblastoma, H3K27M-altered diffuse midline glioma, Group 3 medulloblastoma, AT/RT, and ETMR (embryonal tumor with multilayered rosettes).
• High signal (↑): Necrosis and high cellular turnover. Rapid tumor-cell turnover, treatment-related cell death, and necrotic tumor regions may increase release of fragmented DNA, intracellular proteins, and membrane-bound particles into the CSF compartment. This mechanism is most relevant in aggressive or post-treatment tumors. However, the relationship between radiologic necrosis and measurable CSF signal remains context- and assay-dependent. Examples include glioblastoma with central necrosis, progressive DIPG after radiotherapy, post-treatment AT/RT, and recurrent Group 3 medulloblastoma.
• Low signal (↓): Low-grade, circumscribed growth. Slow proliferation and intact blood–brain and blood–tumor barriers limit shedding into CSF. Cytology, ctDNA, and protein analytes are frequently undetectable or at background levels. The intact capsule of circumscribed tumors acts as a physical barrier to CSF egress. False-negative rates for all CSF analytes are highest in this category. Examples include cerebellar pilocytic astrocytoma (WHO grade 1), DNET (dysembryoplastic neuroepithelial tumor), ganglioglioma, and hypothalamic pilocytic astrocytoma.
• Variable signal (↓↓/Variable): Post-treatment, low-burden disease. After effective therapy, tumor mass and shedding both decrease, often making conventional analytes undetectable. However, residual or recurrent micro-disease may escape cytology and imaging while still being detectable by ultrasensitive ctDNA or methylation-based approaches. Signal is highly dependent on residual tumor volume, clonal architecture, and the sensitivity of the assay platform. Examples include post-HDCT (high-dose chemotherapy) medulloblastoma surveillance, DIPG on ONC201 treatment, residual ependymoma after radiotherapy, and AT/RT in the maintenance phase.

Detailed Signal Factors by Tumor Context

The following list summarizes the key categories from the source table, organized for readability.

1. Tumor interface with CSF compartment: When the tumor abuts a CSF-contiguous surface, expected detection is high (↑).
2. Leptomeningeal dissemination (M2–M3 spread): Expected detection is very high (↑↑).
3. Aggressive, invasive phenotype (high-grade biology): Expected detection is high (↑).
4. Tumor cell death and lysis (necrosis/high turnover): Expected detection is high (↑).
5. Indolent, compact lesion (low-grade, circumscribed growth): Expected detection is low (↓).
6. MRD/surveillance (post-treatment, low-burden disease): Expected detection is variable.

From Tumor to Clinical Answer: A Biological Framework

The review's central figure summarizes the biological and translational logic that underpins CSF liquid biopsy in pediatric CNS tumors. It can be understood in five layers.

1. Different sampling routes interrogate different compartments. Lumbar, ventricular, cisternal, shunt-derived, external ventricular drain (EVD)-derived, Ommaya-derived (from a small reservoir placed under the scalp), and intraoperative specimens are not biologically interchangeable. They differ in tumor proximity, CSF flow dynamics, and background cellular or protein content.
2. Tumor state and its anatomical relationship to CSF spaces shape analyte recovery. Tumors that directly contact ventricular or subarachnoid surfaces, along with leptomeningeal or disseminated disease, are expected to yield stronger CSF signal. Deep, non-contacting circumscribed tumors and post-treatment low-burden states typically produce weaker or more intermittent signal.
3. Biological determinants of biomarker yield include the extent of tumor–CSF interface, leptomeningeal dissemination, high-grade/invasive/necrotic biology, low-grade circumscribed growth, and treatment-related reduction in tumor burden.
4. Tumor-associated analytes recoverable from CSF include cells and cytology, cfDNA and ctDNA, RNA and microRNA, extracellular vesicles, proteins, and metabolites.
5. Clinically relevant outputs supported by these analytes include staging, tissue-sparing molecular diagnosis, tumor classification, measurable residual disease detection, response monitoring, relapse detection, and resistance or clonal evolution analysis.

Together, the framework shows that CSF liquid-biopsy performance depends on tumor anatomy, shedding biology, and clinical context — not on the test alone.

Pre-Analytical and Technical Factors That Determine Test Success

The performance of CSF biomarkers in pediatric neuro-oncology depends not only on tumor biology and how sensitive an assay is, but also on how specimens are obtained, processed, stored, and matched to the intended analytical platform. This matters especially in children, where CSF samples are often low-volume, low-input, and contain a low fraction of tumor material. Under these conditions, small differences in collection, processing, storage, or assay selection can determine whether a low-level tumor signal is detected at all. As a result, pre-analytical variation — everything that happens before the actual lab test is run — is often a primary determinant of analytical success and interpretability.

Specimen Acquisition: Not All CSF Samples Are Equivalent

A first major layer of variability arises at specimen acquisition. CSF compartments are not biologically interchangeable. Lumbar, ventricular, cisternal, shunt-derived, external ventricular drain-derived, Ommaya-derived, and intraoperative samples differ in tumor proximity, CSF flow dynamics, and background cellular and protein content. The decision about where and when to sample is therefore not a trivial detail — it directly affects what the test can reveal.

The source review also documents that early postoperative CSF samples are especially vulnerable to blood contamination or to procedure-related confounding, which can further reduce the reliability of downstream molecular testing. Sampling during or shortly after surgery may introduce blood-derived DNA that dilutes or masks the tumor signal, especially in pediatric samples where the tumor fraction is already low.

Clinical Implications for Patients and Families

For families of children with CNS tumors, this review carries several practical implications.

First, CSF already plays an important clinical role and is not an experimental test. In medulloblastoma, AT/RT, and germ cell tumors, CSF testing may already guide staging and treatment decisions — including whether craniospinal radiation is recommended and at what intensity.

Second, CSF liquid biopsy is being expanded beyond cell-based cytology into molecular testing that can support diagnosis, classification, and monitoring. This means that in the near future, a small CSF sample could conceivably provide information that today requires a surgical biopsy or repeated imaging.

Third, the authors emphasize that CSF testing does not replace other tools. It is a complement — not a substitute — for tissue biopsy, imaging, plasma testing, and conventional cytology.

Fourth, the value of CSF testing depends on the specific clinical situation. For tumors that touch CSF spaces (such as intraventricular ependymoma) or that have spread (such as medulloblastoma with dissemination), tumor signal is more often detected in the fluid, although in ependymoma overall CSF testing at diagnosis has very low clinical yield. For deep, circumscribed, low-grade tumors (such as cerebellar pilocytic astrocytoma), it is more likely to yield false negatives. Families should be counseled that a negative CSF result does not rule out disease.

Limitations and Cautions

Several limitations should temper expectations.

• Conventional CSF cytology has limited sensitivity. Sensitivity for detecting tumor cells is only about 30–70% in medulloblastoma, and much of this depends on M-stage. In ependymoma, the overall rate of leptomeningeal-positive disease at diagnosis is only about 5–10%.
• Sampling safety is a real concern. Lumbar puncture may be contraindicated in patients with herniation risk, mass effect, brainstem involvement, or raised intracranial pressure.
• Blood contamination confounds interpretation and is common in early postoperative samples.
• Young age complicates testing. Most AT/RT patients are under 3 years old, making lumbar puncture technically harder and CSF interpretation more challenging.
• Established markers have important caveats. AFP may be physiologically elevated in infants under 1 year old. CSF PLAP lacks standardization. Normal markers do not exclude germ cell tumors, especially pure germinoma.
• No validated CSF staging system exists for some tumor types such as non-DMG pediatric high-grade glioma.
• Emerging ctDNA/cfDNA and methylation approaches remain investigational for diffuse midline glioma and several other tumor types.
• Rapid disease progression in aggressive tumors like AT/RT can limit the usefulness of sequential sampling.
• Molécular subgroup status may not be captured by current conventional CSF testing.
• The review is narrative, not systematic. No formal risk-of-bias assessment or quantitative evidence grading was performed, and evidence from adult studies was included selectively.

Practical Recommendations

Based on the review, the following points can guide discussions between families and their care teams.

1. Understand that CSF testing is a decision-support tool, not a universal screen. It is most helpful when the tumor is expected to release material into the fluid — for example, disseminated or high-grade tumors — and when results are likely to change treatment.
2. Ask your care team what a CSF result will change. If the answer is "nothing," the test may not add value. If it could change staging, radiation dose, treatment intensity, or trial eligibility, it is likely worth doing.
3. Interpret negative results cautiously. A negative CSF test does not rule out disease, especially in low-grade or well-circumscribed tumors.
4. Timing matters. Postoperative lumbar puncture for medulloblastoma staging is generally performed at least 14 days after surgery to reduce blood contamination.
5. Sampling site matters. Lumbar, ventricular, shunt, and Ommaya samples are not interchangeable. Discuss with the care team which route is most informative for your child's tumor.
6. Ask about molecular CSF testing when appropriate. Emerging tests such as LP-WGS of cfDNA and methylation-based classification may offer additional information beyond standard cytology, though many of these remain investigational.
7. Advocate for standardized handling. Because pre-analytical factors strongly affect results, ask whether the CSF sample will be processed and stored according to the requirements of the intended assay.

The authors conclude that CSF liquid biopsy is unlikely to replace tissue or imaging, but is increasingly positioned to complement both in precision pediatric neuro-oncology — providing targeted molecular information at specific clinical decision points where no other test can.

Frequently Asked Questions

What is cerebrospinal fluid (CSF) testing, and is it already used for children with brain tumors?

CSF is the clear fluid that surrounds the brain and spinal cord. Testing it is already an established clinical specimen in pediatric neuro-oncology, not an experimental test. It is used mainly to check for tumor spread (dissemination) and, in germ cell tumors, to measure markers such as AFP and beta-hCG that guide diagnosis and treatment.

Why might CSF testing be more informative than a blood test for a child's brain tumor?

CSF sits right next to the brain and spinal cord, so it is generally closer to the tumor than blood. The blood–brain barrier also limits how much tumor material passes into the bloodstream. Because of this proximity and limited transfer, CSF can carry more tumor-derived DNA, cells, RNA, proteins, and other substances than plasma.

Does CSF liquid biopsy replace a tissue biopsy or imaging for my child?

No. The authors frame CSF liquid biopsy as a complement, not a substitute, for tissue biopsy, imaging, plasma testing, and conventional cytology. It is most useful at specific clinical decision points where it provides information that cannot be reliably obtained from less invasive or already-established methods, and where that information could change diagnosis, staging, treatment, or monitoring.

If my child's CSF test is negative, does that mean there is no tumor?

No. A negative CSF result does not rule out disease. It may reflect low shedding, limited contact between the tumor and CSF spaces, a low tumor fraction in the sample, or treatment-related suppression of analyte release. False-negative rates are highest in low-grade, well-circumscribed tumors, and conventional cytology sensitivity is only about 30–70% in medulloblastoma.

When is CSF testing likely to be most useful for a child with a brain tumor?

It is most useful when the tumor is expected to release material into the fluid — for example, tumors touching CSF spaces, disseminated or high-grade tumors — and when results are likely to change care. Ask your care team what a CSF result will change. If it could change staging, radiation dose, treatment intensity, or trial eligibility, it may be worth doing.

What are the risks or practical concerns of collecting CSF from a child?

Lumbar puncture may be contraindicated in children with herniation risk, mass effect, brainstem involvement, or raised intracranial pressure. Early postoperative samples are especially vulnerable to blood contamination, which can mask tumor signal. Young age, as in most AT/RT patients under 3 years, makes lumbar puncture technically harder and CSF interpretation more challenging.

What does it mean that CSF testing is 'decision-dependent' or a 'decision-support tool'?

It means CSF testing is most valuable at specific clinical decision points where it provides information that cannot be reliably obtained from other methods and is likely to change diagnosis, risk stratification, treatment selection, monitoring, relapse detection, or clinical trial eligibility. It is not a universal screen, and if a result would not change anything, the test may not add value.

My child has medulloblastoma and the team is recommending craniospinal radiation based on CSF cytology — when should we seek a second opinion?

A second opinion is worth considering when a CSF result is driving a major treatment decision. In medulloblastoma, positive CSF cytology corresponds to M1 disease and can upstage the tumor to high-risk, changing whether craniospinal irradiation is used and at what dose. Because cytology sensitivity is only about 30–70% and post-surgical blood contamination can confound interpretation, reviewing the sampling timing, route, and staging alongside neuraxis MRI matters. A negative result does not exclude disease. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Cerebrospinal Fluid in Pediatric Neuro-Oncology: Molecular Diagnosis, Disease Monitoring, and Clinical Translation.

Authors: Bolatov A, Zhakupov A, Sapargaliyeva M, Abdikadirova A, Xu X, Bayanova M.

Affiliations: Guangdong Key Laboratory for Genome Stability & Disease Prevention and Carson International Cancer Center, Marshall Laboratory of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, China; and Clinical-Academical Department of Laboratory Medicine, Pathology, and Genetics, "University Medical Center" Corporate Fund, Astana, Kazakhstan

Journal: International Journal of Molecular Sciences (Int. J. Mol. Sci.), 2026, Volume 27, Article 5010

Publication details: Received 11 May 2026; Revised 28 May 2026; Accepted 30 May 2026; Published 1 June 2026

DOI: https://doi.org/10.3390/ijms27115010

Article type: Narrative review (open access, published under a Creative Commons Attribution CC BY license)

Note: This patient-friendly article is based on peer-reviewed research. All numerical data, study findings, and clinical conclusions are drawn directly from the original publication. This article is intended for educational purposes and does not replace discussion with a qualified medical professional. Families should discuss specific testing decisions with their child's care team.